KDR and cancer: This activity is more potent than those of clinically used antiangiogenic cancer drugs including bevacizumab (IC50 = 0.15 nM for VEGF-A), ramucirumab (IC50 = 1-2 nM for VEGFR-2), and the tyrosine receptor kinase inhibitor sunitinib (IC50 = 80 nM for VEGFR-2) in endothelial cell culture conditions [36, 38, 42].